Kenneth A Krohn Selected Research

Therapeutics

1/2021	18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study.
1/2021	18F-Fluoroestradiol PET Imaging in a Phase II Trial of Vorinostat to Restore Endocrine Sensitivity in ER+/HER2- Metastatic Breast Cancer.
1/2017	Estrogen Receptor Binding (18F-FES PET) and Glycolytic Activity (18F-FDG PET) Predict Progression-Free Survival on Endocrine Therapy in Patients with ER+ Breast Cancer.
10/2016	Glioma FMISO PET/MR Imaging Concurrent with Antiangiogenic Therapy: Molecular Imaging as a Clinical Tool in the Burgeoning Era of Personalized Medicine.
1/2016	Temporal Heterogeneity of Estrogen Receptor Expression in Bone-Dominant Breast Cancer: 18F-Fluoroestradiol PET Imaging Shows Return of ER Expression.
8/2015	18F-Fluoromisonidazole Quantification of Hypoxia in Human Cancer Patients Using Image-Derived Blood Surrogate Tissue Reference Regions.
3/2015	F-18 fluoromisonidazole for imaging tumor hypoxia: imaging the microenvironment for personalized cancer therapy.
5/2009	Quantitative metrics of net proliferation and invasion link biological aggressiveness assessed by MRI with hypoxia assessed by FMISO-PET in newly diagnosed glioblastomas.
6/2008	Tumor receptor imaging.
2/2008	Positron emission tomography-guided conformal fast neutron therapy for glioblastoma multiforme.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Kenneth A Krohn Research Topics

Disease

44	Neoplasms (Cancer) 01/2021 - 04/2002
19	Hypoxia (Hypoxemia) 05/2022 - 04/2004
11	Breast Neoplasms (Breast Cancer) 01/2021 - 04/2004
8	Glioblastoma (Glioblastoma Multiforme) 05/2022 - 12/2002
8	Glioma (Gliomas) 01/2020 - 04/2002
5	Brain Neoplasms (Brain Tumor) 01/2020 - 07/2002
3	Disease Progression 10/2016 - 10/2006
3	Head and Neck Neoplasms (Head and Neck Cancer) 06/2008 - 04/2004
2	Sarcoma (Soft Tissue Sarcoma) 04/2011 - 04/2004
1	Pathologic Processes 01/2018
1	Carcinogenesis 06/2008
1	Pheochromocytoma 02/2006
1	Lung Neoplasms (Lung Cancer) 02/2005
1	Hematologic Neoplasms (Hematological Malignancy) 01/2005

Drug/Important Bio-Agent (IBA)

15	fluoromisonidazoleIBA 05/2022 - 04/2004
9	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 01/2021 - 12/2002
9	Estrogen ReceptorsIBA 01/2021 - 06/2006
8	alovudineIBA 05/2015 - 05/2004
7	ThymidineIBA 05/2015 - 07/2002
6	Aromatase InhibitorsIBA 01/2021 - 06/2006
5	Glucose (Dextrose)FDA LinkGeneric 01/2020 - 04/2002
4	Oxygen (Dioxygen)IBA 01/2018 - 05/2004
4	Estrogens (Estrogen)FDA Link 01/2017 - 06/2008
4	Biomarkers (Surrogate Marker)IBA 01/2017 - 11/2005
4	NucleosidesIBA 11/2012 - 12/2003
4	DNA (Deoxyribonucleic Acid)IBA 01/2005 - 07/2002
3	Tamoxifen FDA LinkGeneric 07/2011 - 06/2006
3	EnzymesIBA 09/2010 - 12/2003
2	Fulvestrant (Faslodex)FDA Link 01/2017 - 07/2011
2	Cytotoxins (Cytolysins)IBA 03/2015 - 01/2005
2	thiamine triphosphorate (TTP)IBA 05/2008 - 12/2002
2	copper (II) diacetyl- di(N(4)- methylthiosemicarbazone)IBA 04/2007 - 01/2005
2	antibiotic K 4 (K 4)IBA 02/2005 - 02/2005
1	pembrolizumabIBA 05/2022
1	human ERBB2 proteinIBA 01/2021
1	Estradiol (Delestrogen)FDA LinkGeneric 01/2021
1	Histone Deacetylase InhibitorsIBA 01/2021
1	Vorinostat FDA Link 01/2021
1	Bevacizumab (Avastin)FDA Link 10/2016
1	4'-thiothymidineIBA 05/2015
1	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 04/2011
1	thymidine kinase 1IBA 09/2010
1	GadoliniumIBA 01/2009
1	Radioisotopes (Radionuclides)IBA 06/2008
1	Lactic Acid (Lactate)FDA LinkGeneric 06/2008
1	Transcription Factors (Transcription Factor)IBA 05/2008
1	RadiopharmaceuticalsIBA 06/2007
1	Carbonic Anhydrases (Carbonic Anhydrase)IBA 10/2006
1	Hypoxia-Inducible Factor 1IBA 10/2006
1	IsoenzymesIBA 10/2006
1	3-Iodobenzylguanidine (Iobenguane)IBA 02/2006
1	NucleotidesIBA 02/2005
1	Cytostatic AgentsIBA 01/2005
1	Deoxyglucose (2 Deoxy D glucose)IBA 04/2002

Therapy/Procedure

24	Therapeutics 01/2021 - 07/2002
8	Radiotherapy 01/2020 - 04/2002
2	Drug Therapy (Chemotherapy) 01/2020 - 05/2008
1	Immunotherapy 05/2022
1	Chemoradiotherapy 01/2020
1	Precision Medicine 10/2016
1	Electrodes (Electrode) 06/2008
1	Conformal Radiotherapy 04/2007
1	Adrenalectomy 02/2006
1	Cell Transplantation 01/2005
1	Radioimmunotherapy 01/2005
1	Aftercare (After-Treatment) 07/2002